Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779431 | 0.90 | PTGDR2 (0.37) | PTGDR2TSHRGAAHTTSMN1; SMN2 | |
| SCHEMBL3777868 | 0.85 | TSHR (0.39) | PTGDR2TSHRGAAHTTSMN1; SMN2 | |
| SCHEMBL3776184 | 0.84 | TSHR (0.36) | PTGDR2TSHRGAAHTTSMN1; SMN2 | |
| SCHEMBL3779461 | 0.83 | ALDH1A1 (0.41) | PTGDR2PLA2G2AKMT2AGAASMN1; SMN2 | |
| SCHEMBL3779428 | 0.82 | PTGDR2 (0.36) | PTGDR2TSHRPLA2G2AGAAHTT | |
| SCHEMBL2575631 | 0.82 | ERAP1 (0.35) | MEN1KMT2AGAASMN1; SMN2PDE10A | |
| SCHEMBL2573624 | 0.82 | ALDH1A1 (0.34) | PTGDR2PLA2G2AMEN1KMT2AHTT | |
| SCHEMBL534053 | 0.81 | MAOB (0.34) | PTGDR2PLA2G2AKMT2ACDK9 | |
| SCHEMBL3777589 | 0.79 | TSHR (0.40) | PTGDR2TSHRGAAHTTSMN1; SMN2 | |
| SCHEMBL3778224 | 0.79 | ALDH1A1 (0.37) | MEN1KMT2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | PTGDR2 75/4885TSHR 447/4885PI4KB 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.